Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
EVGN similar filings
- 21 Sep 23 Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
- 19 Sep 23 Company Presentation Eyal Ronen, CEO September 2023
- 13 Sep 23 Current report (foreign)
- 23 Aug 23 Current report (foreign)
- 17 Aug 23 Evogene Reports Second Quarter 2023 Financial Results
- 8 Aug 23 Company Presentation August 2023
- 17 Jul 23 Current report (foreign)
Filing view
External links
Exhibit 99.1
Lavie Bio Introduction August 2023
Forward looking statement This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the “Company”) and its parent, Evogene Ltd. (“Evogene”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements.Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, product pipeline, future sales, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. 2
Lavie Bio – In a Nutshell Ag-Biologicals Rapidly GrowingMarket Unique AI Tech-Platform and Data Assets Broad &DiversePipeline 8 programs –new product launch expected every 1-2 years Leveraging AI technology to increase: Microbe selection predictability by 10X Microbe efficiency by 20% The ag-biologicals market is expected to grow at a double digit CAGR Strategic Partners & Investors 2 Revenue Generating Graduated Programs
The Challenge Grow more food with less environmental impact Efficiency Sustainability Climate Change Unstable weather patterns Drought & higher temperatures Increased extreme weather Pest & Disease Outbreaks Deregulation of existing pesticides Resistance development to chemicals Fewer new product introductions Regulatory Restrictions Limiting the use of chemicals Enforcing regenerative practices Regulating food imports Consumer Demands Healthier food Higher quality Sustainable production
5 Ag-biologicals is relatively a newcomer to the huge $200B ag-inputs market Chemical Fertilizers $130B $60B $10B Ag-Biologicals * The amounts described herein are based on Markets and Markets, Research and Markets, Vantage Market Research and company’s analysis Crop Protection Chemicals
10 16 26 12.9% CAGR E * Company estimations, based on data shared by Dunham Trimmer during ABIM 2022, as well as reports from Markets and Markets, Research and Markets, Vantage Market Research Sustainability Renewable resources Increased uptake of fertilizers Consumer Health Less residues Less applicator exposure Regenerative Agriculture Improving soil fertility Integrated pest management Ag-Biologicals Could be the Solution Driving healthier crops, while preserving the soil
Chemical Crop Protection & Fertilizers Ag-Biologicals Today Next Generation ? Sustainability + +++ +++ Efficacy +++ ++ +++ Consistency +++ + +++ Commercial viability +++ + +++ However,Ag-Biologicals are Strugglingstill not efficient as ‘traditional’ solutions Efficiency
Lavie Bio – Next Generation Ag-BiologicalsEfficient & Sustainable Products Chemical Crop Protection & Fertilizers Ag-Biologicals Today Ag-Biologicals Sustainability + +++ +++ Efficacy +++ ++ +++ Consistency +++ + +++ Commercial viability +++ + +++ Efficiency
9 Our Mission Improve food quality, sustainabilityand agriculture productivity through microbiome based, AI-driven, ag-biological products
The Power of the Microbiome Billions of microbes make a difference! Billions of microbes integral to plant-related ecosystems impact the entire plant lifecycle Surrounding microbes generate nature’s largest ‘function bank’ for plant growth and development These microbes act as a ‘live engine’ supporting yield production in the field
Commercialization Optimization Discovery ApprovedProduct The challenge: finding the winning candidates out of a vast number of possible microbes that address a complex myriad of criteria, to reach successful products Ag-Biological Product Development The ultimate case of finding “the needle in the haystack” Product Candidates
12 Lavie Bio’s proprietary BDD platform leverages advanced computational technologies that incorporate deep scientific understanding together with big data and advanced AI, to successfully discover & guide the development of novel ag-biological products Lavie Bio’s Tech Edge: The Biology Driven Design (BDD) Platform BIG DATA BIOLOGY AI Powered by
crop, region, disease, weather conditions, yield… Clear product requirements The platform increases microbe selection predictability by 10X Efficacy, shelf life, drought tolerance, nutrient uptake… World leading microbial bank Microbiomegene pool Microbiomefunction catalog Identify min microbes with max functions Translate requirementsinto functions Lead Product Candidates BDD Platform - Function-Based Product Discovery Decoding the natural diversity of genetic functionality
The increases microbe efficiency by ~20% Genetics Fermentation Formulation ExistingBiologicals Existing Chemicals Efficiency Identify functions for optimization Efficiency ExistingBiologicals Existing Chemicals Optimize functions – proprietary methods Efficacy, shelf life, drought tolerance, nutrient uptake… BDD Platform - Function-Based Product Optimization Maximizing performance of leading microbes Ready for commercialization Lead Product Candidates
Discovery billions > promising few Optimization promising few > product Commercialization product > global expansion End-to-End CapabilitiesFrom product concept to commercialization
Lavie Bio –Breaking the Efficiency/ Sustainability Trade-off High Low Low High Efficiency Efficacy Consistency Commercial Viability Sustainability Chemical Crop Protection & Fertilizers Ag-Biologicals(today) 16 Case Study - Thrivus
Efficiency - Proven Capabilities Bio-inoculant for cereal grains* Sold in USA**& expanding globally Superior performancethan alternatives Consistent performance providing a 4:1 ROI to farmers Check 2% 1% 3% 4% 6% Other Ag-Biologicals Control Yield improvement (%) 5% *Thrivus has regulatory approval in the US & Canada for all small grains including wheat, Barley, Durum, Oats, soybeans, canola, and others. Data was gathered in large side-by-side field trials in the US ** In 2023 Thrivus was sold for wheat and Durum. 2023 trials for barley and oats look promising for potential 2024 expansion
Sustainability - Proven Capabilities Bio-inoculant for cereal grains Growers are financially rewarded for advancing sustainability Use Thrivus bioinoculant for $8/acre Realize yield improvement of ± 4 bushels per acre on average from Thrivus Enroll in the Ceres Global sustainability program As part of the Ceres program, paid upon delivery a $2.50/acre premium for advancing sustainability (subsidized by food companies) * Thrivus is a combination of 2 synergistic bacteria strains which improve nutrient availability & uptake, improving plant health
Product program Product focus Application Target market* Potential expansion** 2022 2023 2024 2025 2026 2027 2028 Bio-Stimulants Seed treatment, Spring wheat North America 25M ACRES wheat North America 500M ACRES LAV228 Bio-stimulants 2 Seed treatment Soy N.A, Europe 85M ACRESsoy US 180M ACRES Bio-stimulants 3 Foliar treatment Soy Brazil, US & LATAM 100M ACRESsoy Brazil 140M ACRES Bio-stimulants 4 Foliar treatment Cotton Brazil, US, India 40M ACREScotton Brazil, US, & India 90M ACRES Bio-Pesticides Fruit rots Foliar treatment Fruits & Veg Europe. N.A <$200M grapes chemicals usage +$800M Additional Fruits & Veg LAV321 Downey mildew Foliar treatment Fruits & Veg Europe. N.A <$350M grapes chemicals usage +$150M Additional Fruits & Veg LAV332 Seedling disease (Pythium) Seed treatment, Corn, soy, F&V Europe, N.A <$500M <$200M LAV441, LAV442 Bio-Insecticides Seed treatment, Corn, soy Europe, N.A <$1.5B existing traits and chemicals market <$500M * Company estimations for the target market of initial crops and disease based on FAO, OECD & USDA data ** Company estimations for total addressable market including potential geographies & crop expansions Expected product launch year Our Product PipelineAn engine for new product launch every 1-2 years product launch year
Product ExampleA bio-control product for vineyards (fruit rot) Consistent performance in preventative application over 3 years (validated by Corteva) Superior performance compared to competing biological control products, similar results to chemicals Integrated spray programs showed potential reduction of 3-5 chemical applications* per season Potential annual product sales >$100m** Untreated Chemical * Program included alternating applications between chemical and LAV311 across the season. ** Lavie Bio’s assessment *
Product ExampleA bio-control for vineyards & vegetables (Downey Mildew & Late Blight) Field proven against Downy Mildew (grapes) & Late Blight (potato & tomato) 2 years testing by 4 multinationals with consistent performance & strong results Limited solutions in the market due to pest resistance and regulatory constraints Potential annual productsales >$100m* * Lavie Bio’s assessment Control Control
Single Product Market PotentialFrom focused development to large market potential HRS Wheat Durum Soy Barley Oats Canola Regions USA Canada Europe India LATAM Australia Turkey Brazil One country/ one crop USA/HRS wheat Multiple countries/ Multiple crops Crops 2023
Business Model Direct model Lavie Bio product End-to-end product development Production by contractor Commercialization via direct channels Revenues from sales Licensing model Lavie Bio ‘tech-inside’ product End-to-end product development Licensing by industry leader Commercialization & production by partner Revenues from upfront payment, milestones & royalties +
Direct Model G2M Step 1 Bottom-up demand generation and sales through regional distribution partners Current Thrivus US distribution partners G2M Step 2 Scale-up through national partners Potential US national partners
Licensing Model Corteva to license Lavie Bio’s bio-fungicide LAV311 & LAV312 for fruit rot Global exclusive license upon reaching diligence milestones Deal terms: Deal includes LAV311 as main strain and LAV312 as a back-up $5M upfront payment Future milestone payments Royalties from future sales
Strategic Investors & Partners Strategic partner:Exclusive long-term license for MicroBoost AI technology for agriculture Strategic partner:2 joint bio-pesticide development programs Strategic partner:2 joint bio-stimulant development programs Global leader incomputational biology Global leader in seeds and ag-chemical products Global leader in fertilizers and specialty minerals Strategic Investor:Evogene holdings – 70% Strategic Investor:Corteva holdings – 28%$27M investment (Aug 2019)* *Includes $10M cash investment along with transfer of assets Strategic Investor:$10M SAFE investment (Aug 2022)
Russel Putland | EVP Commercial and US General Manager 30+ years of ag commercial leadership roles with ‘ground up’ experience in large multi-national organizations We’ve gotthe right team to nurture it Management Team Board of Directors Ofer Haviv Chairman of the board Evogene’s President and CEO Elad Aharonson President, Growing Solutions at ICL Frederic C. Beudot Global Portfolio Leader for Biologicals at Corteva Agriscience Trevor Thiessen Senior agriculture executive, experienced in marketing, sales, and go-to-market Amit Noam | CEO An extensive experience in the agriculture and healthcare sectors, leading teams in the development and execution of commercialization strategies, driving long-term growth and value-creation for businesses Michael Ionesco| VP Research Innovative research leader with deep biotechnology, big data and informatics expertise Dor Kestecher | VP Business Development 10+ years of broad experience leading in agriculture product management, strategy, and development Amir Bercovitz| VP Development Extensive development and product expertise in the ag-biologicals field for 30+ years – led introductions of 5 commercial products Sassi Masliah Vice President Corporate Development at Evogene Yaron EldadCFO Over 25 years of experience in various CFO positions in public and private technology and biotechnology companies,
Summary C Broad & diverse pipeline of 8 bio-stimulant and bio-pesticide products targeting a new product launch every 1-2 years B Unique tech edge – enables to systematically bring sustainable ag-biological products to the market, with comparable efficiency to synthetic solutions D Proven end-to-end product development capabilities with 2 graduated programs generating revenues: Thrivus (direct model) & LAV311 (licensing model) A Ag-biologicals - a $10B market, forecasted to grow at a 13% CAGR over the next decade E Strong market acknowledgement - Corteva, ICL & Evogene as strategic investors & partners
Thank you!